VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.

Published

Journal Article

Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in ccRCC, with cognate enhancer-target genes associated with tissue-specific aspects of malignancy. Superenhancer profiling identified ZNF395 as a ccRCC-specific and VHL-regulated master regulator whose depletion causes near-complete tumor elimination in vitro and in vivoVHL loss predominantly drives enhancer/superenhancer deregulation more so than promoters, with acquisition of active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes. Mechanistically, VHL loss stabilizes HIF2α-HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 without overtly affecting preexisting promoter-enhancer interactions. Subtype-specific driver mutations such as VHL may thus propagate unique pathogenic dependencies in ccRCC by modulating epigenomic landscapes and cancer gene expression.Significance: Comprehensive epigenomic profiling of ccRCC establishes a compendium of somatically altered cis-regulatory elements, uncovering new potential targets including ZNF395, a ccRCC master regulator. Loss of VHL, a ccRCC signature event, causes pervasive enhancer malfunction, with binding of enhancer-centric HIF2α and recruitment of histone acetyltransferase p300 at preexisting lineage-specific promoter-enhancer complexes. Cancer Discov; 7(11); 1284-305. ©2017 AACR.See related commentary by Ricketts and Linehan, p. 1221This article is highlighted in the In This Issue feature, p. 1201.

Full Text

Duke Authors

Cited Authors

  • Yao, X; Tan, J; Lim, KJ; Koh, J; Ooi, WF; Li, Z; Huang, D; Xing, M; Chan, YS; Qu, JZ; Tay, ST; Wijaya, G; Lam, YN; Hong, JH; Lee-Lim, AP; Guan, P; Ng, MSW; He, CZ; Lin, JS; Nandi, T; Qamra, A; Xu, C; Myint, SS; Davies, JOJ; Goh, JY; Loh, G; Tan, BC; Rozen, SG; Yu, Q; Tan, IBH; Cheng, CWS; Li, S; Chang, KTE; Tan, PH; Silver, DL; Lezhava, A; Steger, G; Hughes, JR; Teh, BT; Tan, P

Published Date

  • November 2017

Published In

Volume / Issue

  • 7 / 11

Start / End Page

  • 1284 - 1305

PubMed ID

  • 28893800

Pubmed Central ID

  • 28893800

Electronic International Standard Serial Number (EISSN)

  • 2159-8290

International Standard Serial Number (ISSN)

  • 2159-8274

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.cd-17-0375

Language

  • eng